• レポートコード:MRC2303H053 • 出版社/出版日:360iResearch / 2022年10月11日 • レポート形態:英語、PDF、220ページ • 納品方法:Eメール(受注後2-3日) • 産業分類:医療 |
Single User(1名利用、印刷可) | ¥742,350 (USD4,949) | ▷ お問い合わせ |
Enterprise License(企業利用、印刷可) | ¥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社の当調査資料によると、2021年に888.70百万ドルであった世界のクリティカルケア診断市場規模は2022年に1,045.90百万ドルとなり、2027年までに年平均17.86%成長して2,382.80百万ドルまで拡大すると見込まれています。当書は、クリティカルケア診断の世界市場を対象とした調査・分析結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、検査別分析(凝固検査、フローサイトメトリー、血液検査、免疫タンパク質検査、微生物&感染症検査)、エンドユーザー別分析(救急治療室、集中治療室、手術室)、地域別分析(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)、競争状況、企業情報などの内容を掲載しています。なお、当書内の企業情報としては、Abbott Laboratories、Alere, Inc.、Atlas Medical LLC、Bayer Healthcare AG、Beckman Coulter Inc.、Becton, Dickinson & Company、Bio-Rad Laboratories, Inc.、BioMerieux, Inc.、Biosave、Chembio Diagnostic Systems, Inc.、Covance Inc、Danaher Corporationなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のクリティカルケア診断市場規模:検査別 - 凝固検査の市場規模 - フローサイトメトリーの市場規模 - 血液検査の市場規模 - 免疫タンパク質検査の市場規模 - 微生物&感染症検査の市場規模 ・世界のクリティカルケア診断市場規模:エンドユーザー別 - 救急治療室における市場規模 - 集中治療室における市場規模 - 手術室における市場規模 ・世界のクリティカルケア診断市場規模:地域別 - 南北アメリカのクリティカルケア診断市場規模 アメリカのクリティカルケア診断市場規模 カナダのクリティカルケア診断市場規模 ブラジルのクリティカルケア診断市場規模 ... - アジア太平洋のクリティカルケア診断市場規模 日本のクリティカルケア診断市場規模 中国のクリティカルケア診断市場規模 インドのクリティカルケア診断市場規模 韓国のクリティカルケア診断市場規模 台湾のクリティカルケア診断市場規模 ... - ヨーロッパ/中東/アフリカのクリティカルケア診断市場規模 イギリスのクリティカルケア診断市場規模 ドイツのクリティカルケア診断市場規模 フランスのクリティカルケア診断市場規模 ロシアのクリティカルケア診断市場規模 ... - その他地域のクリティカルケア診断市場規模 ・競争状況 ・企業情報 |
The Global Critical Care Diagnostics Market size was estimated at USD 888.70 million in 2021 and expected to reach USD 1,045.90 million in 2022, and is projected to grow at a CAGR 17.86% to reach USD 2,382.80 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Critical Care Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Test, the market was studied across Coagulation Testing, Flow Cytometry, Hematology, Immunoproteins, Microbial and Infectious Diseases, and Routine & Special Chemistry.
Based on End-User, the market was studied across Emergency Rooms, Intensive Care Units, and Operation Rooms.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Critical Care Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Critical Care Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Critical Care Diagnostics Market, including Abbott Laboratories, Alere, Inc., Atlas Medical LLC, Bayer Healthcare AG, Beckman Coulter Inc., Becton, Dickinson & Company, Bio-Rad Laboratories, Inc., BioMerieux, Inc., Biosave, Chembio Diagnostic Systems, Inc., Covance Inc, Danaher Corporation, EKF Diagnostics, F. Hoffmann-La Roche, General Electric Company, Horiba, Ltd, Johnson and Johnson Service, Inc., Medcaptain Medical Technology Co., Ltd, Medtronic Plc., Nova Biomedical Corporation, Omron Corporation, Orsense LTD, Roche Diagnostics Ltd., Siemens Healthcare Diagnostics, Sysmex Corporation, Thermo Fisher Scientific, and WerfenLife, S.A..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Critical Care Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Critical Care Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Critical Care Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Critical Care Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Critical Care Diagnostics Market?
6. What is the market share of the leading vendors in the Global Critical Care Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Critical Care Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing demand for rapid diagnosis and treatment
5.1.1.2. Rising geriatric population worldwide
5.1.1.3. Rapidly incorporated new technologies
5.1.1.4. Growth in data management and connectivity to Electronic Health Record (EHR)
5.1.2. Restraints
5.1.2.1. High cost of diagnostics tools
5.1.3. Opportunities
5.1.3.1. Government activities and support for implementing critical care diagnostics
5.1.3.2. Rising remote communications between diagnostics and laboratories
5.1.4. Challenges
5.1.4.1. Lack of Skilled Professionals
5.2. Cumulative Impact of COVID-19
6. Critical Care Diagnostics Market, by Test
6.1. Introduction
6.2. Coagulation Testing
6.3. Flow Cytometry
6.4. Hematology
6.5. Immunoproteins
6.6. Microbial and Infectious Diseases
6.7. Routine & Special Chemistry
7. Critical Care Diagnostics Market, by End-User
7.1. Introduction
7.2. Emergency Rooms
7.3. Intensive Care Units
7.4. Operation Rooms
8. Americas Critical Care Diagnostics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Critical Care Diagnostics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Critical Care Diagnostics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abbott Laboratories
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Alere, Inc.
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Atlas Medical LLC
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Bayer Healthcare AG
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. Beckman Coulter Inc.
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Becton, Dickinson & Company
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. Bio-Rad Laboratories, Inc.
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. BioMerieux, Inc.
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Biosave
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Chembio Diagnostic Systems, Inc.
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. Covance Inc
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Danaher Corporation
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. EKF Diagnostics
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. F. Hoffmann-La Roche
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. General Electric Company
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
12.16. Horiba, Ltd
12.16.1. Business Overview
12.16.2. Key Executives
12.16.3. Product & Services
12.17. Johnson and Johnson Service, Inc.
12.17.1. Business Overview
12.17.2. Key Executives
12.17.3. Product & Services
12.18. Medcaptain Medical Technology Co., Ltd
12.18.1. Business Overview
12.18.2. Key Executives
12.18.3. Product & Services
12.19. Medtronic Plc.
12.19.1. Business Overview
12.19.2. Key Executives
12.19.3. Product & Services
12.20. Nova Biomedical Corporation
12.20.1. Business Overview
12.20.2. Key Executives
12.20.3. Product & Services
12.21. Omron Corporation
12.21.1. Business Overview
12.21.2. Key Executives
12.21.3. Product & Services
12.22. Orsense LTD
12.22.1. Business Overview
12.22.2. Key Executives
12.22.3. Product & Services
12.23. Roche Diagnostics Ltd.
12.23.1. Business Overview
12.23.2. Key Executives
12.23.3. Product & Services
12.24. Siemens Healthcare Diagnostics
12.24.1. Business Overview
12.24.2. Key Executives
12.24.3. Product & Services
12.25. Sysmex Corporation
12.25.1. Business Overview
12.25.2. Key Executives
12.25.3. Product & Services
12.26. Thermo Fisher Scientific
12.26.1. Business Overview
12.26.2. Key Executives
12.26.3. Product & Services
12.27. WerfenLife, S.A.
12.27.1. Business Overview
12.27.2. Key Executives
12.27.3. Product & Services
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing